University of Thessaly (UTH)
Αξιολόγηση δραστικότητας νανοσωματιδίων έναντι πολυανθεκτικών βακτηρίων
Abstract
dc:descriptionThe increasing frequency of multidrug resistant bacterial infections in nosocomial settings is widely recognized as one of the most urgent public health problems. The main directions to compact the dire consequences of the multidrug resistance threat are: a) the multifaceted containment of the spreading of multidrug resistant (MDR) strains and b) the development of new therapeutic approaches. Among the latter, the use of cyclodextrin based nanocarriers has been proposed for the targeted carrying of antibiotic substances at the site of infection (improving their pharmacokinetic properties) as well as for their protection from antimicrobial resistance mechanisms. Furthermore, modified and antibiotic free nanoparticles could be used either as direct antimicrobial agents or as indirect inhibitors of important resistance mechanisms. In this study, we examined natural and modified nanoparticles and cyclodextrins for their properties either as carriers of clinically available antimicrobial agents, as direct antimicrobial compounds or as indirect ones, exerting inhibitory properties against the main antimicrobial resistance mechanisms. The positively charged octacis (6-(2-aminomethyl)-6-deoxy)-γ-cyclodextrin (γ-Cys), produced by N.C.S.R. Demokritos, in preliminary studies was shown to produce strong complexes with the penicillin oxacillin, protecting it from the carbapenamase Oxa-1, reducing the hydrolysis rate in photometric studies. In-vitro, the γ-Cys cyclodextrin presented a desirable toxicological profile, as it did not exhibit signs of cytotoxicity even in high concentrations. Lastly, we determined its ability to enter in macrophages, carrying its antimicrobial load and significantly increasing its intracellular concentration. We also examined modified cyclodextrins for their applications as inhibitors against resistant mechanisms such as efflux pumps and MBLs. The AMBnTßCD cyclodextrins, produced by Innovative Biologics (U.S.A.), are modified with 7 positive charged subunits (7+ß-CD) and were studied as inhibitors for the RND efflux systems, produced by clinical strains of Α. baumannii. In in-vitro studies, they successfully re-sensitized clinical strains producing such efflux systems in the antibiotics tetracycline and ciprofloxacin. Their re-sensitizing properties were proven both in MIC determination studies and in time-kill assays. In these assays the bacterial load was reduced by at least 1,5 log10 in the presence of nanomolar concentrations of the AMBnTßCD compared to the free antibiotic, at the end of a 24 hour incubation. The modified cyclodextrins, produced by N.C.S.R. Demokritos, exhibited significant synergy with newer b-lactams in in-vitro, ex-vivo and in-vivo studies, against MDR Gram-negative clinical strains.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Miliotis, Georgios
- Μηλιώτης, Γεώργιος
Subjects
dc:subject × 18- Νανοσωματίδια
- Κυκλοδεξτρίνες
- Μέταλλο-Β-λακταμάσες
- Πολυανθεκτικά στελέχη
- Gram αρνητικά βακτήρια
- Αντιμικροβιακή αντοχή
- Αντιμικροβιακή δράση
- Nanomedicine
- Cyclodextrins
- Multidrug resistance
- Antibacterial action
- Adjuvant treatment
- Carbapenems
- Carbapenemases
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45784